TC Medical(SH:600763) Sou Hu Cai Jing·2025-12-15 12:16Core Viewpoint - Tongce Medical (600763) reported a slight decline in stock price, with a closing price of 40.25 yuan on December 15, 2025, down 0.57% [1] Financial Performance - For the first three quarters of 2025, Tongce Medical achieved a main revenue of 2.29 billion yuan, an increase of 2.56% year-on-year [2] - The net profit attributable to shareholders was 514 million yuan, up 3.16% year-on-year, while the net profit excluding non-recurring items was 509 million yuan, increasing by 3.09% year-on-year [2] - In Q3 2025, the company reported a single-quarter main revenue of 842 million yuan, a year-on-year increase of 2.34% [2] - The single-quarter net profit attributable to shareholders was 192 million yuan, up 2.31% year-on-year, and the net profit excluding non-recurring items was also 192 million yuan, increasing by 1.85% year-on-year [2] - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan [2] - The gross profit margin is reported at 41.69% [2] Market Activity - On December 15, 2025, the net inflow of main funds was 1.6042 million yuan, accounting for 1.15% of the total transaction amount, while retail funds saw a net inflow of 9.405 million yuan, making up 6.74% of the total transaction amount [1] - Conversely, speculative funds experienced a net outflow of 11.0092 million yuan, representing 7.89% of the total transaction amount [1] Analyst Ratings - In the last 90 days, seven institutions provided ratings for Tongce Medical, with four giving a "buy" rating and three an "increase" rating [2] - The average target price set by institutions over the past 90 days is 5.288 billion yuan [2]